22nd Century Group Inc (NYSEAMERICAN:XXII) Director Purchases $17,160.00 in Stock

22nd Century Group Inc (NYSEAMERICAN:XXII) Director Nora B. Sullivan bought 22,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was purchased at an average cost of $0.78 per share, with a total value of $17,160.00. Following the completion of the transaction, the director now owns 308,523 shares in the company, valued at $240,647.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of NYSEAMERICAN XXII opened at $0.74 on Friday. 22nd Century Group Inc has a 52-week low of $0.60 and a 52-week high of $2.46.

22nd Century Group (NYSEAMERICAN:XXII) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $7.10 million during the quarter.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA boosted its position in shares of 22nd Century Group by 110.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 36,637 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 19,202 shares during the period. SG Americas Securities LLC acquired a new stake in shares of 22nd Century Group in the 1st quarter valued at about $50,000. Advisor Group Inc. lifted its position in 22nd Century Group by 25.9% during the 4th quarter. Advisor Group Inc. now owns 53,440 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 11,000 shares during the period. Raymond James Financial Services Advisors Inc. lifted its position in 22nd Century Group by 30.5% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 100,035 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 23,387 shares during the period. Finally, Alliancebernstein L.P. lifted its position in 22nd Century Group by 87.1% during the 1st quarter. Alliancebernstein L.P. now owns 122,000 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 56,800 shares during the period.

22nd Century Group Company Profile

22nd Century Group, Inc, a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM research cigarettes for use in independent clinical studies.

Recommended Story: Strangles

Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.